<html xmlns:v="urn:schemas-microsoft-com:vml" xmlns:o="urn:schemas-microsoft-com:office:office" xmlns:w="urn:schemas-microsoft-com:office:word" xmlns:m="http://schemas.microsoft.com/office/2004/12/omml" xmlns="http://www.w3.org/TR/REC-html40"><head><meta http-equiv=Content-Type content="text/html; charset=us-ascii"><meta name=Generator content="Microsoft Word 12 (filtered medium)"><!--[if !mso]><style>v\:* {behavior:url(#default#VML);}
o\:* {behavior:url(#default#VML);}
w\:* {behavior:url(#default#VML);}
.shape {behavior:url(#default#VML);}
</style><![endif]--><style><!--
/* Font Definitions */
@font-face
{font-family:"Cambria Math";
panose-1:2 4 5 3 5 4 6 3 2 4;}
@font-face
{font-family:Calibri;
panose-1:2 15 5 2 2 2 4 3 2 4;}
@font-face
{font-family:Tahoma;
panose-1:2 11 6 4 3 5 4 4 2 4;}
@font-face
{font-family:Verdana;
panose-1:2 11 6 4 3 5 4 4 2 4;}
@font-face
{font-family:Webdings;
panose-1:5 3 1 2 1 5 9 6 7 3;}
/* Style Definitions */
p.MsoNormal, li.MsoNormal, div.MsoNormal
{margin:0cm;
margin-bottom:.0001pt;
font-size:11.0pt;
font-family:"Calibri","sans-serif";}
a:link, span.MsoHyperlink
{mso-style-priority:99;
color:blue;
text-decoration:underline;}
a:visited, span.MsoHyperlinkFollowed
{mso-style-priority:99;
color:purple;
text-decoration:underline;}
p.MsoAcetate, li.MsoAcetate, div.MsoAcetate
{mso-style-priority:99;
mso-style-link:"Balloon Text Char";
margin:0cm;
margin-bottom:.0001pt;
font-size:8.0pt;
font-family:"Tahoma","sans-serif";}
span.BalloonTextChar
{mso-style-name:"Balloon Text Char";
mso-style-priority:99;
mso-style-link:"Balloon Text";
font-family:"Tahoma","sans-serif";}
span.EmailStyle19
{mso-style-type:personal;
font-family:"Calibri","sans-serif";
color:windowtext;}
span.EmailStyle20
{mso-style-type:personal-reply;
font-family:"Calibri","sans-serif";
color:#1F497D;}
.MsoChpDefault
{mso-style-type:export-only;
font-size:10.0pt;}
@page WordSection1
{size:612.0pt 792.0pt;
margin:72.0pt 72.0pt 72.0pt 72.0pt;}
div.WordSection1
{page:WordSection1;}
--></style><!--[if gte mso 9]><xml>
<o:shapedefaults v:ext="edit" spidmax="1026" />
</xml><![endif]--><!--[if gte mso 9]><xml>
<o:shapelayout v:ext="edit">
<o:idmap v:ext="edit" data="1" />
</o:shapelayout></xml><![endif]--></head><body lang=EN-CA link=blue vlink=purple><div class=WordSection1><p class=MsoNormal><span style='color:#1F497D'>Hi all:<o:p></o:p></span></p><p class=MsoNormal><span style='color:#1F497D'>Interesting note, below, from Janssen wrt Zytiga.<o:p></o:p></span></p><p class=MsoNormal><span style='color:#1F497D'><o:p> </o:p></span></p><p class=MsoNormal><span style='color:#1F497D'>Take care,<o:p></o:p></span></p><p class=MsoNormal><span style='color:#1F497D'>Glen<o:p></o:p></span></p><p class=MsoNormal><span style='color:#1F497D'>Chair PCCN W-W<o:p></o:p></span></p><p class=MsoNormal><span style='color:#1F497D'><o:p> </o:p></span></p><div><div style='border:none;border-top:solid #B5C4DF 1.0pt;padding:3.0pt 0cm 0cm 0cm'><p class=MsoNormal><b><span lang=EN-US style='font-size:10.0pt;font-family:"Tahoma","sans-serif"'>From:</span></b><span lang=EN-US style='font-size:10.0pt;font-family:"Tahoma","sans-serif"'> Mimeault, Isabelle-Anne [JOICA] [mailto:imimeaul@its.jnj.com] <br><b>Sent:</b> June 25, 2013 4:28 PM<br><b>To:</b> Undisclosed recipients:<br><b>Subject:</b> Health Canada extend indication for ZYTIGA<o:p></o:p></span></p></div></div><p class=MsoNormal><o:p> </o:p></p><p class=MsoNormal><span lang=EN-US>Good afternoon to you all,<o:p></o:p></span></p><p class=MsoNormal><span lang=EN-US>I wanted to communicate with you personally in letting you know the good news – Health Canada expanded indication for Zytiga in men with metastatic prostate cancer.<o:p></o:p></span></p><p class=MsoNormal><span lang=EN-US>Please see attached a link that PCC has posted on their website (scroll down to May 29<sup>th</sup> for the release):<o:p></o:p></span></p><p class=MsoNormal><span style='color:#1F497D'><a href="http://www.prostatecancer.ca/Support/Resources/Prostate-Cancer-News-Archive">http://www.prostatecancer.ca/Support/Resources/Prostate-Cancer-News-Archive</a> . This is a fantastic news as it provides them with another treatment option.</span><span lang=EN-US><o:p></o:p></span></p><p class=MsoNormal><span style='color:#1F497D'><o:p> </o:p></span></p><p class=MsoNormal><span style='color:#1F497D'>I am also attaching a CTV clip for you to have a look at. It includes a clip from a Zytiga prostate cancer patient and valuable feedback from Dr. Fleschner.</span> <span lang=EN-US><a href="http://www.ctvnews.ca/video?clipId=949750">http://www.ctvnews.ca/video?clipId=949750</a></span><span style='color:#1F497D'><o:p></o:p></span></p><p class=MsoNormal><span style='color:#1F497D'><o:p> </o:p></span></p><p class=MsoNormal><span style='color:#1F497D'>I would really appreciate if you could let me know if you decide to share this exciting news with your members via your PCCN’s newsletter/website/Facebook/Twitter etc. so more people can be aware. This can change/improves someone’s life!<o:p></o:p></span></p><p class=MsoNormal><span style='color:#1F497D'><o:p> </o:p></span></p><p class=MsoNormal><span style='color:#1F497D'>Many thanks,<o:p></o:p></span></p><p class=MsoNormal><span style='color:#1F497D'><o:p> </o:p></span></p><p class=MsoNormal><span lang=EN-US><o:p> </o:p></span></p><p class=MsoNormal><span lang=EN-US style='font-size:10.0pt;font-family:"Verdana","sans-serif";color:black'>Isabelle-Anne Mimeault<o:p></o:p></span></p><p class=MsoNormal><span lang=EN-US style='font-size:10.0pt;font-family:"Verdana","sans-serif";color:black'>Manager, Community Relations National & Ontario<o:p></o:p></span></p><p class=MsoNormal><span lang=EN-US style='font-size:10.0pt;font-family:"Verdana","sans-serif";color:black'><img border=0 width=374 height=119 id="Picture_x0020_1" src="cid:image002.jpg@01CE71C1.05689590" alt="Janssen_Hor_RGB"><o:p></o:p></span></p><p class=MsoNormal><span lang=EN-US style='font-size:10.0pt;font-family:"Verdana","sans-serif";color:black'>Janssen, Inc<o:p></o:p></span></p><p class=MsoNormal><span lang=EN-US style='font-size:10.0pt;font-family:"Verdana","sans-serif";color:black'>Phone: 416.382.5000 #2134 Phone: 1.800.387.8781 #2134 Fax: 416.449.2658<br></span><span lang=EN-US style='font-size:10.0pt;font-family:"Arial","sans-serif"'><a href="mailto:imimeaul@its.jnj.com">imimeaul@its.jnj.com</a></span><span lang=EN-US style='font-size:10.0pt;font-family:"Verdana","sans-serif";color:black'><o:p></o:p></span></p><p class=MsoNormal><span lang=EN-US style='font-size:10.0pt;font-family:"Verdana","sans-serif";color:black'><o:p> </o:p></span></p><p class=MsoNormal style='text-autospace:none'><i><span lang=EN-US style='font-size:8.0pt;font-family:"Verdana","sans-serif";color:gray'>Confidentiality Notice: This e-mail transmission is confidential and may be privileged information that is intended only for the individual or entity named in the e-mail address. If you are not the intended recipient and believe you have received this e-mail transmission in error, please reply to the sender, so that we can arrange for proper delivery, and then please delete the message from your inbox. The unauthorized use, dissemination, distribution or reproduction of this e-mail, including attachments, is prohibited and may be unlawful. Receipt by anyone other than the intended recipient(s) is not a waiver of any attorney/client or other privilege. Thank you.<o:p></o:p></span></i></p><p class=MsoNormal style='text-autospace:none'><u><span lang=EN-US style='font-size:8.0pt;font-family:"Verdana","sans-serif";color:gray'><o:p><span style='text-decoration:none'> </span></o:p></span></u></p><p class=MsoNormal><span lang=EN-US style='font-size:10.0pt;font-family:Webdings;color:#5E9629'>P</span><span lang=EN-US style='color:#1F497D'> </span><span lang=EN-GB style='font-size:10.0pt;font-family:"Arial","sans-serif";color:#5E9629'>Please consider the environment before printing this email</span><span lang=EN-US style='font-size:12.0pt;font-family:"Times New Roman","serif";color:#1F497D'><o:p></o:p></span></p><p class=MsoNormal><span lang=EN-US style='font-size:10.0pt'><o:p> </o:p></span></p><p class=MsoNormal><span lang=EN-US><o:p> </o:p></span></p><p class=MsoNormal><span lang=EN-US><o:p> </o:p></span></p></div></body></html>